Anbio Biotechnology

NNNN

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

About the company

Country: GermanyPrice: $3.82Market Cap: $167.7M

Investment snapshot

6%positive consensus

Scored 1d ago

Positive

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

$1.16

-69.6% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

Verdict	Meaning
BUY	Positive purchase signal: the framework's buy requirements are met.
PASS	The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRAL	Neither a positive nor negative conclusion. It does not mean to hold an existing position.
FAIL	The company does not clear the framework's requirements.
Ranked	Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

Metric	Graham Defensive Value	Buffett Quality Compounder	Lynch GARP	Greenblatt Magic Formula	Piotroski F-Score	Dreman Contrarian Value	Munger Quality Focus	Pabrai Dhandho Framework	Akre Three-Legged Stool	Marks Risk-Aware Value	Ackman Activist Value	Templeton Global Bargain Hunter	Sleep Scale Economies Shared	Asness Systematic Factors	Neff Low-P/E Total Return	Schloss Asset-Value Discipline	O'Shaughnessy Systematic Factor Composite
Verdict	FAIL	FAIL	FAIL	Not ranked	PASS	FAIL	FAIL	FAIL	FAIL	FAIL	FAIL	FAIL	FAIL	NEUTRAL	FAIL	FAIL	NEUTRAL
Score
Analysis	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…
Intrinsic Value (annual)		N/A	N/A		N/A	N/A	N/A			N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Margin of Safety	-153.0%	N/A	N/A	-547.5%	N/A	N/A	N/A	-371.6%	-7.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financial Basis	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-02-01–2026-11-01 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-02-01–2026-11-01 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-04-07 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-02-01–2026-11-01 Latest source filing: 2026-04-07 Score computed: 2026-11-14

Where It Passes

Where It Falls Short

Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS
✗Graham<= 15x
Price-to-Book Ratio5.5x
✗Graham<= 1.5x
P/E x P/B
✗Graham<= 22.5
Basic earnings-growth PEG (dividends excluded)
✗Lynch< 1.0 (ideally < 0.5)
EBIT / Enterprise Value3.6%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=3.6%, ROC=None
✗GreenblattBoth EY > 10% and ROC > 25%
Price / EPS26.0x
✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
Price / (CFO / Shares)N/A (negative CFPS)
✗Dreman< 8x
Price / Book Value per Share5.5x
✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
Valuation ReasonablenessP/E=26.0x
✗MungerP/E < 25 or Owner Earnings Yield > 5%
P/E or FCF YieldP/E=26.0x
✗PabraiP/E < 15 or FCF Yield > 10%
P/B or P/E vs. Historical AverageP/E=26.0x, P/B=5.5x
✗MarksP/E < 15 or P/B < 2.0
Discount to Intrinsic Value
✗Marks>= 20% below intrinsic value
Price / FCF per Share
✗Ackman<= 25
Price vs. Trailing Low103% of trailing low ($3.72)
✓Templeton<= 120% of trailing low (certified split-adjusted live window)
Net income / market capitalization+3.82%; #2084/6340 (top 32.9%)
✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Positive book equity / market capitalization+0.1799; #4294/6449 (top 66.6%)
✗AsnessTop 30% of eligible cross-section
Price / Diluted EPS26.0x
✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
(EPS CAGR % + Dividend Yield %) / P/E
✗Neff> 0.7 (Neff's published traditional edge)
Price / Tangible Book Value per Share5.53x
✗SchlossP/TBV <= 1.00x (app cutoff)
Book Value per Share Change
✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
Revenue / market capitalization+0.0516; #4572/5247 (top 87.1%)
✗OshaughnessyTop 10% of eligible cross-section
(Operating cash flow - capex) / market capitalization
✗OshaughnessyTop 10% of eligible cross-section
Trailing six-month price return through the evaluation date-85.90%; #5927/6202 (top 95.6%)
✗OshaughnessyTop 10% of eligible cross-section
Valuation models0% pass✗ 4▾
NNNN overvalued: all 4 models price fair value below $3.82 (median $1.16)
Graham fair value$1.51
✗Graham-153.0% margin vs $3.82
Greenblatt fair value$0.59
✗Greenblatt-547.5% margin vs $3.82
Pabrai fair value$0.81
✗Pabrai-371.6% margin vs $3.82
Akre fair value$3.55
✗Akre-7.6% margin vs $3.82
Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict
✗GrahamFAIL (1/9)✗BuffettFAIL (2/9)✗LynchFAIL (2/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (3/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag NNNN's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets
✗GrahamLT Debt <= Net Current Assets
Debt/Equity & Interest Coverage
✗BuffettD/E < 0.5 AND Interest Coverage > 5x
Total Debt / Equity
✗Lynch< 0.33
Cash - Long-term Debt
✗LynchPositive preferred
LT Debt / Total Assets Change0.00% -> 0.00%
✓PiotroskiDecreased YoY
Current Assets / Current Liabilities344.31
✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
Total Debt / Shareholders' Equity
✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
Debt Levels
✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
Interest Coverage & Debt/EBITDA
✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
Total Debt / Shareholders Equity
✗Ackman<= 1.0
Negative debt-to-equity (higher means less debt)
✗AsnessTop 30% of eligible cross-section
Cash Flow10% pass✓ 1✗ 11▾
9 of 10 flag NNNN's cash flow — Buffett, Lynch, Piotroski +6 more
Free Cash Flow Proxy
✗BuffettPositive and growing
FCF Positive and Growing
✗LynchPositive and growing
Operating Cash Flow$-6.7M
✗PiotroskiCFO > 0
(CFO / Total Assets) vs ROACFO/Assets=-22.28%, ROA=21.17%
✗PiotroskiCFO/Assets > ROA
Price / (CFO / Shares)N/A (negative CFPS)
✗Dreman< 8x
P/E or FCF YieldP/E=26.0x
✗PabraiP/E < 15 or FCF Yield > 10%
FCF Positive
✗MarksPositive FCF in majority of recent years
(OCF - CapEx) / Market Cap
✗Ackman>= 4%
Price / FCF per Share
✗Ackman<= 25
Positive Operating Cash Flow frequency3/4 years positive
✓SleepPositive OCF in >= 70% of available years
Operating Cash Flow - Capital Expenditures
✗Neff> $0 (app proxy for a strong fundamental case)
(Operating cash flow - capex) / market capitalization
✗OshaughnessyTop 10% of eligible cross-section
Profitability13% pass✓ 13✗ 22▾
14 of 16 flag NNNN's profitability — Graham, Buffett, Lynch +11 more
Positive EPS (10 years)4/4 years positive
✗GrahamPositive EPS every year for 10 years
EPS Growth (3-yr avg, 10-yr window)
✗Graham>= 33% growth
Net Income Positive (10+ years)4/4 years positive
✗BuffettPositive every year for 10+ years
ROE (up to 5-year arithmetic mean)32.5%
✓Buffett> 15% arithmetic mean (app rule)
Operating Margin (10-yr trend)66.7% (latest)
✓BuffettStable or rising over 10 years
Free Cash Flow Proxy
✗BuffettPositive and growing
Earnings Variance (10-yr CoV)
✗BuffettCoV < 0.3
Retained Earnings Effectiveness
✗Buffett$1 retained -> > $1 market value created
Basic earnings-growth PEG (dividends excluded)
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR
✗Lynch15-30% (Fast Grower); > 0% to pass
ROE21.2%
✓Lynch> 15%
EBIT / Enterprise Value3.6%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=3.6%, ROC=None
✗GreenblattBoth EY > 10% and ROC > 25%
Net Income / Total Assets21.17%
✓PiotroskiROA > 0
ROA Change YoY12.54% -> 21.17% (delta: +8.63%)
✓PiotroskiCurrent ROA > Prior ROA
(CFO / Total Assets) vs ROACFO/Assets=-22.28%, ROA=21.17%
✗PiotroskiCFO/Assets > ROA
Gross Margin Change YoY71.9% -> 87.2%
✓PiotroskiImproved YoY
Pre-Tax Income / Revenue74.1%
✓Dreman>= 8%
Net Income / Shareholders' Equity21.2%
✓Dreman> 12%
Margin of SafetyP/E=26.0x, P/B=5.5x
✗PabraiP/B < 1.5 or P/E < 15
Return on Equity16.7% (3-yr avg)
✗AkreROE > 20% (3-year avg)
Discount to Intrinsic Value
✗Marks>= 20% below intrinsic value
Positive Net Income Frequency4/4 years positive
✓MarksPositive net income in >= 7 of last 10 years
Operating Income / Revenue66.7%
✓Ackman>= 15%
Net Income / Shareholders Equity21.2%
✓Ackman>= 15%
5-Year EPS CAGR
✗Templeton> 0% (5-year EPS CAGR)
Operating Margin Trend29.2% (2023) -> 66.7% (2025)
✓TempletonNon-negative operating-margin trend over 3 years
Revenue growth vs. gross and operating margin trendgross margin 50.1% -> 87.2%, operating margin 29.2% -> 66.7%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
Net income / market capitalization+3.82%; #2084/6340 (top 32.9%)
✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Gross profit / total assets+24.94%; #1729/3702 (top 46.7%)
✗AsnessTop 30% of eligible cross-section
Net income / positive book equity+21.24%; #740/5226 (top 14.2%)
✓AsnessTop 30% of eligible cross-section
Negative 5-year standard deviation of ROA-0.0373; #2190/5884 (top 37.2%)
✗AsnessTop 30% of eligible cross-section
3-5 Year Diluted EPS CAGR
✗Neff7%-20% annualized
Positive Diluted-EPS Years
✗Schloss>= 70% positive over 5-10 observed years (app rule)
Growth13% pass✓ 3✗ 10▾
7 of 8 flag NNNN's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)
✗Graham>= 33% growth
Basic earnings-growth PEG (dividends excluded)
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR
✗Lynch15-30% (Fast Grower); > 0% to pass
Inventory Growth vs Revenue GrowthN/A (no inventory)
✓LynchInventory growth < Revenue growth
EPS Growth Direction
✗DremanPositive over recent years
EPS CAGR
✗Dreman> 5% annualized
Positive Net Income Frequency4/4 years positive
✓MarksPositive net income in >= 7 of last 10 years
3yr Median Revenue Growth5.6%
✓Ackman>= 5%
Positive EPS Growth Frequency
✗AckmanPositive EPS growth in >= 3 of last 5 years
5-Year EPS CAGR
✗Templeton> 0% (5-year EPS CAGR)
Revenue growth vs. gross and operating margin trendgross margin 50.1% -> 87.2%, operating margin 29.2% -> 66.7%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
5-year Revenue CAGR-28.4%
✗SleepCAGR > 7%
3-5 Year Diluted EPS CAGR
✗Neff7%-20% annualized
Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag NNNN's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio344.31
✓Graham>= 2.0
ROIC (3-5 yr avg)
✗Buffett> 10%
ROIC - WACC
✗BuffettPositive (WACC = 10%)
EBIT / (NWC + Net Fixed Assets)
✗Greenblatt> 25%
Current Ratio Change YoY10.71 -> 344.31
✓PiotroskiIncreased YoY
Revenue / Total Assets Change YoY0.43x -> 0.29x
✗PiotroskiImproved YoY
Current Assets / Current Liabilities344.31
✓Dreman> 1.5
Return on Invested Capital
✗Munger> 15%
ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
Reinvestment Rate x ROIC
✗AkreReinvestment Rate * ROIC > 10%
ROIC (5-year)
✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products

SIC Sector: Chemicals & Pharmaceuticals

Size: Micro Cap($167.7M)

Revenue: $8.6M+5.6% YoY

Net Income: $6.4M+169.9% YoY

Financial Snapshot

Operating Margin66.7%

Return on Equity21.2%

Debt / Equity--

Current Ratio344.31

EPS (Diluted)$0.15+162.5% 1y

Shares Retired−3.3%

Similar Companies

MRKMerck & Co., Inc.

$364.3B

ABTABBOTT LABORATORIES

$188.0B

BMYBRISTOL MYERS SQUIBB CO

$129.7B

TECHBIO-TECHNE Corp

$11.4B

Shareholder Return

Fiscal 2025

Issued 3.3% of shares last year.

Buybacks: —
Dividends: —

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY23

−100.0% = −77.5% + −100.0%

FY24

−46.7% = 5.3% + −49.3%

FY25

162.5% = 169.9% + −2.7%

Earnings Fewer shares More shares

The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

Metric	FY 2025 Sources 20-F · 2026-04-07	FY 2024 Sources 20-F · 2025-04-28	FY 2023 Sources 20-F · 2025-04-28	FY 2022 Sources 20-F · 2025-04-28
Market Cap	$167.7Mcurrent	$282.9Mest.	--	--
Revenue	$8.6M↑6%	$8.2M↑22%	$6.7M↓71%	$23.5M
Operating Income	$5.8M↑189%	$2.0M↑2%	$2.0M↓81%	$10.2M
Net Income	$6.4M↑170%	$2.4M↑5%	$2.3M↓77%	$10.0M
EPS (Diluted)	$0.15↑163%	$0.06↓47%	$0.10↓100%	$100112.00
Gross Margin	87.2%↑21%	71.9%↑44%	50.1%↓6%	53.4%
Operating Margin	66.7%↑174%	24.4%↓17%	29.2%↓33%	43.3%
ROE	21.2%↑54%	13.8%↓9%	15.2%↓81%	79.8%
Total Debt	--	--	--	--
Shareholders' Equity	$30.2M↑75%	$17.2M↑16%	$14.8M↑18%	$12.5M
Current Ratio	344.31↑3114%	10.71↓32%	15.86	—
Debt / Equity	—	—	—	—
Operating Cash Flow	-$6.7M↓424%	$2.1M↑132%	$898.4K↓80%	$4.4M
Free Cash Flow	--	--	--	--

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

NNNN vs Peers — Financial Grading

Revenue$8.6MBottom 25%

Net Income$6.4MMedian

ROE21.2%Top 25%

D/E—

Op. Margin66.7%Top 25%

Curr. Ratio344.31Top 25%

Company	Market Cap	Price	Revenue	Net Income	ROE	D/E	Op. Margin	Curr. Ratio	Graham	Buffett	Lynch	Greenblatt	Piotroski	Dreman
Merck & Co., Inc.MRK	$364.3B	$147.76	$65.0B	$18.3B	34.7%	0.94	—	1.54	2/9	5/9	4/7	0/3	F-Score 4	1/11
ABBOTT LABORATORIESABT	$188.0B	$108.52	$44.3B	$6.5B	12.5%	0.25	18.2%	1.58	3/9	4/9	2/7	1/3	F-Score 5	3/11
BRISTOL MYERS SQUIBB COBMY	$129.7B	$63.43	$48.2B	$7.1B	38.2%	2.44	19.4%	1.26	2/9	1/9	3/7	1/3	F-Score 8	5/11
BIO-TECHNE CorpTECH	$11.4B	$72.80	$1.2B	$73.4M	3.8%	—	8.4%	3.46	4/9	3/9	3/7	0/3	F-Score 5	4/11
REPLIGEN CORPRGEN	$10.7B	$167.79	$738.3M	$48.9M	2.3%	0.26	7.5%	8.37	3/9	2/9	3/7	0/3	F-Score 7	5/11
IONIS PHARMACEUTICALS INCIONS	$4.8B	$29.06	$943.7M	$381.4M	-78.0%	3.60	-40.4%	3.83	3/9	1/9	1/7	0/3	F-Score 4	3/11
NEOGEN CORPNEOG	$2.5B	$11.23	$870.4M	$7.9M	-0.4%	0.76	-2.5%	3.82	3/9	1/9	2/7	0/3	F-Score 6	4/11
Pharvaris N.V.PHVS	$2.4B	$33.36	—	$206.4M	-64.8%	0.00	—	—	0/9	0/9	2/7	0/3	F-Score 2	2/11